MedPath

Prothena

🇧🇪Belgium
Ownership
-
Employees
173
Market Cap
$1.1B
Website

Cognition Therapeutics Reveals Promising Biomarker Strategy for Alzheimer's Treatment Patient Selection

Cognition Therapeutics' Phase 2 SHINE study demonstrates that Alzheimer's patients with lower p-tau217 levels showed 95% improvement on ADAS-Cog 11 and 108% better MMSE scores with zervimesine treatment versus placebo.

Prothena's Birtamimab Shows Promise in Phase 3 Trial for AL Amyloidosis with Focus on High-Risk Patients

Prothena's Phase 3 AFFIRM-AL trial evaluates birtamimab in Mayo stage 4 AL amyloidosis patients, targeting a survival benefit with a p-value threshold of 0.10 per FDA agreement.

Inhibikase Halts Parkinson's Drug Development Following Phase II Trial Setback

Inhibikase Therapeutics discontinues development of risvodetinib for Parkinson's disease after Phase II trial fails to show significant efficacy despite meeting safety endpoints.

Eisai's Leqembi Receives Positive Recommendation in Europe, Limited to Specific Genetic Profile

The European Medicines Agency's (EMA) CHMP supports Leqembi's approval for early Alzheimer's, reversing its earlier negative opinion.

Parkinson's Disease Research Focuses on Disease-Modifying Therapies

Research in the seven major markets (7MM) increasingly prioritizes disease-modifying therapies (DMTs) and treatments for non-motor symptoms of Parkinson's disease.

Parkinson's Disease Research Shifts Focus to Disease-Modifying Therapies

Clinical research in Parkinson's disease (PD) is increasingly focused on disease-modifying therapies (DMTs) to address unmet needs beyond motor symptom management.

Parkinson's Disease Research Focuses on Disease-Modifying Therapies

Clinical research in the seven major markets (7MM) for Parkinson's disease (PD) is heavily focused on disease-modifying therapies (DMTs) to address unmet needs.

Parkinson's Disease Research Focuses on Disease-Modifying Therapies

The Parkinson's disease (PD) therapeutic market faces unmet needs, notably the absence of neuroprotective/disease-modifying therapies (DMTs) and treatments for non-motor symptoms.

© Copyright 2025. All Rights Reserved by MedPath